ChromaDex Corp (CDXC)

2.34
0.05 2.09
NASDAQ : Health Care
Prev Close 2.39
Open 2.40
Day Low/High 2.33 / 2.42
52 Wk Low/High 2.46 / 6.18
Volume 85.08K
Avg Volume 113.80K
Exchange NASDAQ
Shares Outstanding 37.90M
Market Cap 88.70M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ChromaDex Names Dr. Matthew Roberts As A New Scientific Advisory Board Member

ChromaDex Names Dr. Matthew Roberts As A New Scientific Advisory Board Member

Company's Scientific Advisory Board Will Be Comprised of a Diverse Range of Experts with an Emphasis on Nicotinamide Riboside

ChromaDex To Report Third Quarter 2016 Financial Results On Thursday, November 10, 2016

ChromaDex To Report Third Quarter 2016 Financial Results On Thursday, November 10, 2016

Company Will Host Investor Conference Call on Thursday, November 10, 2016

Nicotinamide Riboside (NR) Plays A Critical Role In The Most Efficient Path To Cellular Energy Production

Nicotinamide Riboside (NR) Plays A Critical Role In The Most Efficient Path To Cellular Energy Production

Researchers' findings disprove the idea that there's a shortcut to NAD production

Published Studies In Humans And Mice Reveal How A Superior Vitamin B3 May Play An Important Role In Helping Us Enjoy Longer, Healthier Lives

Published Studies In Humans And Mice Reveal How A Superior Vitamin B3 May Play An Important Role In Helping Us Enjoy Longer, Healthier Lives

This vitamin, called NR, is exciting researchers as they discover more about its power to give us a more youthful metabolism

ChromaDex Adds New AnthOrigin™ To Its Proprietary Ingredient Portfolio

ChromaDex Adds New AnthOrigin™ To Its Proprietary Ingredient Portfolio

AnthOrigin™ naturally extracted anthocyanins are ideal for natural, clean label supplement innovation

Update: ChromaDex Will Demonstrate How It's Raising The Bar On Ingredient Technology, Applications Innovation And Raw Materials Testing At SupplySide West 2016

Update: ChromaDex Will Demonstrate How It's Raising The Bar On Ingredient Technology, Applications Innovation And Raw Materials Testing At SupplySide West 2016

Booth to feature a new ingredient introduction, information on the latest published clinical trials, and a new time-saving solution to ensure your products deliver on their promise

ChromaDex Will Demonstrate How It's Raising The Bar On Ingredient Technology, Applications Innovation And Raw Materials Testing At SupplySide West 2016

ChromaDex Will Demonstrate How It's Raising The Bar On Ingredient Technology, Applications Innovation And Raw Materials Testing At SupplySide West 2016

Booth to feature, a new ingredient introduction, information on the latest published clinical trials, and a new time-saving solution to ensure your products deliver on their promise

U.S. FDA Issues GRAS No Objection Letter For NIAGEN®

U.S. FDA Issues GRAS No Objection Letter For NIAGEN®

NR, a vitamin B3, affords food and beverage manufacturers a new opportunity to innovate

ChromaDex Reports Record Revenue As Ingredients Sales Climb 83% Compared To Previous Year Period

ChromaDex Reports Record Revenue As Ingredients Sales Climb 83% Compared To Previous Year Period

-Company Reports Record Revenue of $8.8 Million and Operating Income of $371,000-

ChromaDex To Report Second Quarter 2016 Financial Results On Thursday, August 11, 2016

ChromaDex To Report Second Quarter 2016 Financial Results On Thursday, August 11, 2016

-Company Will Host Investor Conference Call on Thursday, August 11, 2016-

ChromaDex Clinical Trial Studying NIAGEN® Well Underway, With Eight Additional Collaborative Human Studies Active

ChromaDex Clinical Trial Studying NIAGEN® Well Underway, With Eight Additional Collaborative Human Studies Active

Study results will help to define the effective dose range of nicotinamide riboside (NR) in humans when taken daily, over eight weeks.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Into Possible Securities Fraud Violations By Certain Officers And Directors Of ChromaDex Corporation

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Into Possible Securities Fraud Violations By Certain Officers And Directors Of ChromaDex Corporation

Levi & Korsinsky announces it has commenced an investigation of ChromaDex Corporation ("ChromaDex" or the "Company") (NASDAQ:CDXC) concerning possible violations of federal securities laws.

ChromaDex (CDXC) Is Strong On High Volume Today

ChromaDex (CDXC) Is Strong On High Volume Today

Trade-Ideas LLC identified ChromaDex (CDXC) as a strong on high relative volume candidate

ChromaDex Responds To Short Attack

ChromaDex Responds To Short Attack

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against ChromaDex Corporation

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against ChromaDex Corporation

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of ChromaDex Corporation (NASDAQ:CDXC) resulting from allegations that ChromaDex may...